SHUTTLE PHARMACEUTICALS HOLD (SHPH) Fundamental Analysis & Valuation

NASDAQ:SHPH • US8256934014

Current stock price

0.86 USD
-0.04 (-4.05%)
At close:
0.91 USD
+0.05 (+5.81%)
After Hours:

This SHPH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SHPH Profitability Analysis

1.1 Basic Checks

  • In the past year SHPH has reported negative net income.
  • In the past year SHPH has reported a negative cash flow from operations.
  • In the past 5 years SHPH always reported negative net income.
  • In the past 5 years SHPH always reported negative operating cash flow.
SHPH Yearly Net Income VS EBIT VS OCF VS FCFSHPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -302.20%, SHPH is doing worse than 91.71% of the companies in the same industry.
  • SHPH has a Return On Equity of -767.95%. This is in the lower half of the industry: SHPH underperforms 79.19% of its industry peers.
Industry RankSector Rank
ROA -302.2%
ROE -767.95%
ROIC N/A
ROA(3y)-170.32%
ROA(5y)-174.67%
ROE(3y)-496.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SHPH Yearly ROA, ROE, ROICSHPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • SHPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SHPH Yearly Profit, Operating, Gross MarginsSHPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. SHPH Health Analysis

2.1 Basic Checks

  • SHPH has more shares outstanding than it did 1 year ago.
  • SHPH has a worse debt/assets ratio than last year.
SHPH Yearly Shares OutstandingSHPH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50K 100K 150K
SHPH Yearly Total Debt VS Total AssetsSHPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

  • SHPH has an Altman-Z score of -25.58. This is a bad value and indicates that SHPH is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -25.58, SHPH is not doing good in the industry: 86.51% of the companies in the same industry are doing better.
  • SHPH has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of SHPH (0.30) is worse than 67.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Altman-Z -25.58
ROIC/WACCN/A
WACCN/A
SHPH Yearly LT Debt VS Equity VS FCFSHPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

  • SHPH has a Current Ratio of 1.66. This is a normal value and indicates that SHPH is financially healthy and should not expect problems in meeting its short term obligations.
  • SHPH's Current ratio of 1.66 is on the low side compared to the rest of the industry. SHPH is outperformed by 80.15% of its industry peers.
  • SHPH has a Quick Ratio of 1.66. This is a normal value and indicates that SHPH is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.66, SHPH is doing worse than 78.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
SHPH Yearly Current Assets VS Current LiabilitesSHPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SHPH Growth Analysis

3.1 Past

  • SHPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.87%, which is quite good.
EPS 1Y (TTM)9.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. SHPH Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SHPH. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SHPH Price Earnings VS Forward Price EarningsSHPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SHPH Per share dataSHPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SHPH Dividend Analysis

5.1 Amount

  • SHPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SHPH Fundamentals: All Metrics, Ratios and Statistics

SHUTTLE PHARMACEUTICALS HOLD

NASDAQ:SHPH (3/26/2026, 5:56:02 PM)

After market: 0.91 +0.05 (+5.81%)

0.86

-0.04 (-4.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners4.35%
Inst Owner Change-19.27%
Ins Owners1.69%
Ins Owner Change0%
Market Cap4.81M
Revenue(TTM)N/A
Net Income(TTM)-10.71M
AnalystsN/A
Price TargetN/A
Short Float %1.72%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.45
P/tB 3.45
EV/EBITDA N/A
EPS(TTM)-25.87
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2
FCFYN/A
OCF(TTM)-2
OCFYN/A
SpS0
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -302.2%
ROE -767.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-170.32%
ROA(5y)-174.67%
ROE(3y)-496.91%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z -25.58
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.35%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-114.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-115.4%
OCF growth 3YN/A
OCF growth 5YN/A

SHUTTLE PHARMACEUTICALS HOLD / SHPH Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SHUTTLE PHARMACEUTICALS HOLD (SHPH) stock?

ChartMill assigns a fundamental rating of 0 / 10 to SHPH.


What is the valuation status for SHPH stock?

ChartMill assigns a valuation rating of 0 / 10 to SHUTTLE PHARMACEUTICALS HOLD (SHPH). This can be considered as Overvalued.


Can you provide the profitability details for SHUTTLE PHARMACEUTICALS HOLD?

SHUTTLE PHARMACEUTICALS HOLD (SHPH) has a profitability rating of 0 / 10.